IN2014MN02105A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02105A IN2014MN02105A IN2105MUN2014A IN2014MN02105A IN 2014MN02105 A IN2014MN02105 A IN 2014MN02105A IN 2105MUN2014 A IN2105MUN2014 A IN 2105MUN2014A IN 2014MN02105 A IN2014MN02105 A IN 2014MN02105A
- Authority
- IN
- India
- Prior art keywords
- compound
- infection
- treating
- medicament
- treating herpes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261635931P | 2012-04-20 | 2012-04-20 | |
| PCT/US2013/035042 WO2013158367A1 (en) | 2012-04-20 | 2013-04-02 | Cyclopropanecarboxylate esters of purine analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02105A true IN2014MN02105A (es) | 2015-09-11 |
Family
ID=49380678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2105MUN2014 IN2014MN02105A (es) | 2012-04-20 | 2013-04-02 | |
| IN2107MUN2014 IN2014MN02107A (es) | 2012-04-20 | 2013-04-03 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2107MUN2014 IN2014MN02107A (es) | 2012-04-20 | 2013-04-03 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8969361B2 (es) |
| EP (2) | EP2838538B1 (es) |
| JP (2) | JP6177879B2 (es) |
| KR (2) | KR101774861B1 (es) |
| CN (2) | CN104394868A (es) |
| AU (2) | AU2013249708B2 (es) |
| BR (1) | BR112014026182A2 (es) |
| ES (2) | ES2621257T3 (es) |
| IL (2) | IL235097A (es) |
| IN (2) | IN2014MN02105A (es) |
| RU (2) | RU2642463C2 (es) |
| TW (2) | TWI458709B (es) |
| WO (2) | WO2013158367A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
| MA43159B1 (fr) | 2015-11-06 | 2020-08-31 | Hoffmann La Roche | Dérivés d'indoline-2-one |
| CN106831707B (zh) * | 2016-12-28 | 2019-09-20 | 杭州市西溪医院 | 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途 |
| GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| US20240067771A1 (en) | 2020-12-23 | 2024-02-29 | Basf Se | New catalyst for producing polyurethanes |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| CN113999221B (zh) * | 2021-11-04 | 2024-04-05 | 南京中医药大学 | 6-位取代的吲哚酮衍生物及其医药用途 |
| CN114380802B (zh) * | 2022-01-07 | 2023-11-17 | 贵州大学 | 一类含咔唑基咪唑盐类化合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT351865B (de) | 1977-04-01 | 1979-08-27 | Hoffmann La Roche | Akarizide mittel |
| US5543414A (en) * | 1994-07-28 | 1996-08-06 | Syntex (Usa) Inc. | Achiral amino acid acyl esters of ganciclovir and its derivatives |
| DK2020408T3 (da) * | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
| CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US20090264494A1 (en) * | 2002-10-18 | 2009-10-22 | Board Of Regents, The University Of Texas System | Use of neuroprotective 3-substituted indolone compositions |
| US7105563B2 (en) | 2003-10-24 | 2006-09-12 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| WO2006127217A2 (en) * | 2005-05-25 | 2006-11-30 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
| EP1926725A4 (en) | 2005-09-22 | 2010-10-06 | Scripps Research Inst | PROTEIN KINASEINHIBITORS ON ALKOXYINDOLINONE BASE |
| CN1850794A (zh) * | 2006-05-30 | 2006-10-25 | 中国医学科学院医药生物技术研究所 | 3－酰胺基取代苯甲酰脲类化合物及其抗肿瘤作用 |
| MX2009006170A (es) | 2006-12-11 | 2009-06-19 | Irmc Llc | Compuestos y composiciones como inhibidores de cinasa. |
| WO2008071573A2 (en) * | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Powder formulation for valganciclovir |
| EP2167465A1 (en) | 2007-06-12 | 2010-03-31 | Boehringer Ingelheim International GmbH | Indolinone derivatives and their use in treating disease-states such as cancer |
| US7846793B2 (en) | 2007-10-03 | 2010-12-07 | Applied Materials, Inc. | Plasma surface treatment for SI and metal nanocrystal nucleation |
| WO2009111739A2 (en) * | 2008-03-07 | 2009-09-11 | Exley Ray W | Treatment of herpes virus related diseases |
| EP2274311A2 (en) * | 2008-03-28 | 2011-01-19 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Compounds and methods for the treatment of viral infection |
| UY31929A (es) * | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| RU2011103189A (ru) * | 2008-06-30 | 2012-08-10 | Силин Фармасьютикалз, Инк. (Us) | Производные оксиндола |
| US20100298376A1 (en) * | 2009-05-13 | 2010-11-25 | Board Of Regents, The University Of Texas System | Use of novel neuroprotective 3-substituted indolone compositions |
| GB201014374D0 (en) * | 2010-08-27 | 2010-10-13 | Univ Greenwich | Novel hybrid compounds |
| WO2012048235A1 (en) * | 2010-10-08 | 2012-04-12 | Novartis Ag | Vitamin e formulations of sulfamide ns3 inhibitors |
-
2013
- 2013-04-02 ES ES13778039.1T patent/ES2621257T3/es active Active
- 2013-04-02 EP EP13778039.1A patent/EP2838538B1/en not_active Not-in-force
- 2013-04-02 JP JP2015507030A patent/JP6177879B2/ja not_active Expired - Fee Related
- 2013-04-02 KR KR1020147032458A patent/KR101774861B1/ko active IP Right Grant
- 2013-04-02 WO PCT/US2013/035042 patent/WO2013158367A1/en active Application Filing
- 2013-04-02 IN IN2105MUN2014 patent/IN2014MN02105A/en unknown
- 2013-04-02 CN CN201380032742.6A patent/CN104394868A/zh active Pending
- 2013-04-02 US US13/855,692 patent/US8969361B2/en not_active Expired - Fee Related
- 2013-04-02 RU RU2014145481A patent/RU2642463C2/ru not_active IP Right Cessation
- 2013-04-02 AU AU2013249708A patent/AU2013249708B2/en not_active Ceased
- 2013-04-03 CN CN201380020494.3A patent/CN104302287B/zh not_active Expired - Fee Related
- 2013-04-03 JP JP2015507031A patent/JP6174119B2/ja not_active Expired - Fee Related
- 2013-04-03 WO PCT/US2013/035177 patent/WO2013158373A1/en active Application Filing
- 2013-04-03 RU RU2014145480A patent/RU2627706C2/ru not_active IP Right Cessation
- 2013-04-03 EP EP13777764.5A patent/EP2838531B1/en not_active Not-in-force
- 2013-04-03 IN IN2107MUN2014 patent/IN2014MN02107A/en unknown
- 2013-04-03 KR KR1020147031413A patent/KR101778095B1/ko active IP Right Grant
- 2013-04-03 US US13/855,916 patent/US8946282B2/en not_active Expired - Fee Related
- 2013-04-03 AU AU2013249714A patent/AU2013249714B2/en not_active Ceased
- 2013-04-03 BR BR112014026182A patent/BR112014026182A2/pt not_active Application Discontinuation
- 2013-04-03 ES ES13777764.5T patent/ES2600467T3/es active Active
- 2013-04-19 TW TW102113856A patent/TWI458709B/zh not_active IP Right Cessation
- 2013-04-19 TW TW102113981A patent/TWI496784B/zh not_active IP Right Cessation
-
2014
- 2014-10-19 IL IL235097A patent/IL235097A/en not_active IP Right Cessation
- 2014-10-19 IL IL235098A patent/IL235098A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02105A (es) | ||
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| PH12016500538A1 (en) | Inhibitors of kras g12c | |
| MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
| PH12015501965B1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112017021869A2 (pt) | compostos quinazolina substituídos e métodos de uso dos mesmos | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| MX2020002150A (es) | Terapia de combinación para el tratamiento del cáncer. | |
| NZ627277A (en) | Imidazopyrrolidinone compounds | |
| AU2013270326B2 (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| CR20160131A (es) | Formulaciones de (s)-3-(4- ((4- (morfolinometil)benzil) oxi) -1-oxoisoindolin)-2-il) piperidin -2,6-diona | |
| CY1124316T1 (el) | Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα | |
| NZ628392A (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| WO2014081405A3 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | |
| EP4023298A4 (en) | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT IN PATIENTS WITH SPECIFIC GENE MARKER | |
| WO2014015137A3 (en) | Compositions and methods for treating dysproliferative diseases | |
| WO2012045009A3 (en) | Polyphosphate and pyrophosphate derivative of saccharides |